skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Peptides having reduced toxicity that stimulate cholesterol efflux

Abstract

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.

Inventors:
; ;
Publication Date:
Research Org.:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1463293
Patent Number(s):
10,017,551
Application Number:
14/774,682
Assignee:
The Regents of the University of California (Oakland, CA)
DOE Contract Number:  
AC02-05CH11231
Resource Type:
Patent
Resource Relation:
Patent File Date: 2014 Mar 14
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES

Citation Formats

Bielicki, John K., Johansson, Jan, and Danho, Waleed. Peptides having reduced toxicity that stimulate cholesterol efflux. United States: N. p., 2018. Web.
Bielicki, John K., Johansson, Jan, & Danho, Waleed. Peptides having reduced toxicity that stimulate cholesterol efflux. United States.
Bielicki, John K., Johansson, Jan, and Danho, Waleed. 2018. "Peptides having reduced toxicity that stimulate cholesterol efflux". United States. https://www.osti.gov/servlets/purl/1463293.
@article{osti_1463293,
title = {Peptides having reduced toxicity that stimulate cholesterol efflux},
author = {Bielicki, John K. and Johansson, Jan and Danho, Waleed},
abstractNote = {The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.},
doi = {},
url = {https://www.osti.gov/biblio/1463293}, journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Jul 10 00:00:00 EDT 2018},
month = {Tue Jul 10 00:00:00 EDT 2018}
}

Works referenced in this record:

Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency
journal, November 2013


Orally administered peptides synergize statin activity
patent-application, April 2008


Compositions and methods of use for treating cardiovascular disease
patent-application, September 2008


Stabilized alpha helical peptides and uses thereof
patent-application, November 2005


Sustained-delivery of an apolipoproteinE–peptidomimetic using multivesicular liposomes lowers serum cholesterol levels
journal, February 2002


Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux
journal, July 2003


Methods and reagents for modulating cholesterol levels
patent-application, March 2004


Helical synthetic peptides that stimulate cellular cholesterol efflux
patent-application, September 2005


The complete genome sequence of Moorella thermoacetica (f. Clostridium thermoaceticum)
journal, July 2008


Effects of l- or d-Pro incorporation into hydrophobic or hydrophilic helix face of amphipathic α-helical model peptide on structure and cell selectivity
journal, February 2004


Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
patent-application, July 2005


Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat
journal, November 2002


Peptides Having Reduced Toxicity Thar Stimulate Cholesterol Efflux
patent-application, September 2014


Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus
journal, February 1992


Protein Folding: A Glimpse of the Holy Grail?
journal, October 1998


Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox
book, January 1994